← Eichor
Condition: Acute Lymphoblastic Leukemia Adult B Cell Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Acute Lymphoblastic Leukemia Adult B Cell

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Phase 1/Phase 2 · 80 location(s) · AstraZeneca · NCT06137118Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acut
Phase 1/Phase 2 · 13 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05310591CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A
Phase 2 · 2 location(s) · KK Women's and Children's Hospital · NCT05648019Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Phase 1 · 1 location(s) · Belarusian Research Center for Pediatric Oncology, Hematolog · NCT05333302Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lym
Phase 2 · 8 location(s) · City of Hope Medical Center · NCT06918431Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom
Phase 2 · 1 location(s) · University of Washington · NCT07224100A Phase I Dose Finding Study of MB-CART2219.1
Phase 1 · 2 location(s) · University Hospital Tuebingen · NCT07108868Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymph
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07040982Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignanci
Phase 1 · 1 location(s) · University of Kansas Medical Center · NCT06879340Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Phase 1 · 1 location(s) · Stanford University · NCT06408194A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Phase 3 · 5 location(s) · Memorial Sloan Kettering Cancer Center · NCT07223021Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
NA · 1 location(s) · University of Chicago · NCT06785324HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relaps
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05751044Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase 1 · 1 location(s) · CytoCares Inc · NCT06037018Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803"Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL
Phase N/A · 3 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT06919393Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leu
Phase 3 · 460 location(s) · Alliance for Clinical Trials in Oncology · NCT03150693HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Rela
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05745714Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
Phase 1 · 1 location(s) · Bambino Gesù Hospital and Research Institute · NCT06080191A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Mana
NA · 8 location(s) · National Cancer Institute (NCI) · NCT05621291Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Phase 1/Phase 2 · 2 location(s) · Curocell Inc. · NCT04836507Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · 10 location(s) · Fred Hutchinson Cancer Center · NCT03779854ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
Phase 1 · 1 location(s) · National University Hospital, Singapore · NCT05038696Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 · 5 location(s) · Tr1X, Inc. · NCT06462365CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Rel
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT07328503A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 an
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07470073Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06213636
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.